You Position: Home > Paper

Comparison of the Developmental Potential and Clinical Results of In Vivo Matured Oocytes Cryopreserved with Different Vitrification Media

( views:23, downloads:8 )
Author:
No author available
Journal Title:
Chinese Medical Journal
Issue:
22
DOI:
10.4103/0366-6999.169052
Key Word:
Fertilization;Live Birth;Oocytes;Pregnancy;Vitrification Media

Abstract: Background: Oocyte vitrification is widely used throughout the world, but its clinical efficacy is inconsistent and depends on the vitrification media.This study compared the developmental potential and clinical results of in vivo matured oocytes cryopreserved with different vitrification media.Methods: This retrospective study involved vitrified-warmed oocytes at one in vitro fertilization laboratory.Vitrification media kits comprised the MC kit (ethylene glycol [EG] plus 1,2-propanediol [PROH]), the KT kit (EG plus dimethyl sulphoxide [DMSO]), and the Modified kit (EG plus DMSO and PROH kit).Rates of oocyte survival and subsequent developmental potential were recorded and analyzed.The t-test and the Chi-square test were used to evaluate each method's efficacy.Results: Oocyte survival rate was significantly higher for the Modified kit (92.0%) than for the MC kit (88.2%) (P < 0.05) and the KT kit (77.3%) (P < 0.001).The rate of high-quality embryo development in the Modified kit group (35.8%) was significantly higher than in the MC kit group (29.0%) and the KT kit group (28.3%) (P < 0.001).No significant differences were observed in the clinical pregnancy and implantation rates among the MC, KT, and Modified kit groups (37.2% vs.30.2% vs.39.6%;21.9% vs.18.8% vs.27.4%,respectively) (P > 0.05).The high-quality embryo rate per warmed oocyte was significantly higher (23.4%) in the Modified kit group than in the other groups (P < 0.001).The embryo utilization and live birth rates per warmed oocyte were the highest in the Modified kit group, but not significantly (P > 0.05).Conclusions: Modified vitrification media are efficient for oocyte vitrification and, with further verification, may be able to replace commercially available media in future clinical applications.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn